skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
IGF-methotrexate Conjugate (Code C113789)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: IGF-methotrexate Conjugate

Definition: A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.

Label: IGF-methotrexate Conjugate

NCI Thesaurus Code: C113789 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL471770  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
IGF-methotrexate Conjugate

External Source Codes: 
PDQ Closed Trial Search ID 757276
PDQ Open Trial Search ID 757276 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C113789
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom